Home>Topics>Companies>Eli Lilly

Eli Lilly LLY

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Lilly gets tentative approval for diabetes drug

      Headlines

      Tue, 19 Aug 2014

      The FDA grants tentative approval for Eli Lilly ( LLY +0.5% ) and Boehringer Ingelheim's Basaglar (insulin glargine injection) as a treatment to improve glycemic control

    2. UPDATE 1- Eli Lilly insulin drug receives tentative U.S. approval

      Headlines

      Mon, 18 Aug 2014

      Aug 18 (Reuters) - The U.S. Food and Drug Administration granted tentative approval for Eli Lilly and Co and Boehringer Ingelheim's insulin injection that helps control blood sugar levels in diabetes patients, Lilly said in a statement.

    3. Eli Lilly and Co's insulin drug receives tentative approval

      Headlines

      Mon, 18 Aug 2014

      Aug 18 (Reuters) - The U.S. Food and Drug Administration granted tentative approval for Eli Lilly and Co and Boehringer Ingelheim's insulin injection that helps control sugar levels in diabetes patients, said Lilly in a statement.

    4. Eli Lilly : Strong Future Prospects Will Restore The Company's Financials

      Headlines

      Mon, 18 Aug 2014

      Balanced Investing : In the season of earnings release, Eli Lilly and Company (NYSE: LLY ) has also joined the list by ..... 2014 Earnings Presentation Patent expiries have strangled Eli Lilly and Company's quarterly performance this time. This

    5. New Morningstar Analyst Report for MannKind Corp

      Stock Reports

      Wed, 13 Aug 2014

      Safety concerns linking Exubera use to lung cancer in former smokers prompted diabetes experts such as Novo Nordisk and Eli Lilly to discontinue their inhaled insulin products.Afrezza has demonstrated a much more favorable side-effect profile compared

    6. New Morningstar Analyst Report for Cubist Pharmaceuticals Inc

      Stock Reports

      Wed, 13 Aug 2014

      pharmaceutical firm focused on antibiotic treatments. The firm's lead drug, Cubicin, was originally developed by Eli Lilly and launched in 2003 to treat Methicillin-Resistant Staphylococcus Aureus, or MRSA. Cubist acquired Adolor Corp

    7. New Morningstar Analyst Report for Alnylam Pharmaceuticals Inc

      Stock Reports

      Fri, 8 Aug 2014

      directors have impressive qualifications. For example, Steven Paul is a former president of Lilly Research Laboratories at Eli Lilly . Management has waived rights to sizable cash bonuses in favor of stock options, aligning pay with performance. However

    8. Sanofi: Confronting Lantus Patent Expiry With More Efficient Successor Toujeo

      Headlines

      Thu, 7 Aug 2014

      basal insulin, Toujeo. The filing was also accepted by the European Medicines Agency "EMA" for EU countries. Blocking Eli Lilly US Lantus is the world's most widely prescribed insulin . The drug garnered $7.78 billion in sales revenue in the

    9. Novo Nordisk Reports in Line Quarter; Slightly Raising FVE With Tresiba Outcomes Trial Progress

      Commentary

      Thu, 7 Aug 2014

      landscape; Sanofi is poised to launch its own next-generation long-acting insulin Toujeo in the first half of 2015, and Eli Lilly could launch a biosimilar version of Lantus in the second half of 2016. We think Tresiba's prospects for beating biosimilar

    10. Eli Lilly : A Dividend Play And More

      Headlines

      Tue, 5 Aug 2014

      By Northport Investments : Eli Lilly and Company (NYSE: LLY ) is one of our favorite major American pharmaceutical investments. In recent years, there have been

    « Prev12345Next »
    Content Partners